Optune device
Jump to navigation
Jump to search
Indications
- treatment of glioblastoma after after completion of chemoradiation
Procedure
- patient-operated wearable device transmits electrical fields through the scalp to target glioblastoma
- device continuously delivers alternating electrical fields to the brain at an intermediate frequency
Mechanism of action
- thought to disrupt mitosis & cell division in tumor cells[1]
- improves survival but not curative:
- median progression-free survival 6.7 vs 4.0 months
- 2-year survival 43% vs 31%
- 5-year survival 13% vs 5%
More general terms
References
- ↑ 1.0 1.1 Orciari Herman A, Sadoughi S, Sofair A. Wearable Electrical Device Improves Survival in Newly Diagnosed Glioblastoma Physician's First Watch, April 3, 2017 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
Stupp R, Hegi ME, Idbaih A et al CT007 - Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): Final results of a randomized, multi-center, phase III trial. American Association for Cancer Research. 2017 Annual Meeting. Session CTMS01 - Breast Cancer, Ovarian Cancer, and Glioblastoma Clinical Trials. April 2, 2017 http://www.abstractsonline.com/pp8/#!/4292/presentation/12353